Jinxin Fertility : VOLUNTARY ANNOUNCEMENT - BUSINESS EXPANSION PLAN IN LAOS

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jinxin Fertility Group Limited

錦 欣 生 殖 醫 療 集 團 有 限 公 司 *

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 1951)

VOLUNTARY ANNOUNCEMENT

BUSINESS EXPANSION PLAN IN LAOS

The announcement is made by Jinxin Fertility Group Limited (the "Company") on a voluntary basis.

The Company is pleased to announce that for the purpose of its business expansion in Laos, on February 29, 2020, its indirect wholly-owned subsidiary, JXR New Hope Limited has agreed to acquire from Rhea International Medical Centre ("Rhea"), an independent third party, the relevant licenses to provide assisted reproductive services and operate an IVF (in vitro fertilization) clinic in Laos. The Company has planned to set up a new IVF-licensed clinic within the Boten Special Economic Zone in Laos and such clinic with a floor area of approximately 5,000 sq.m. is expected to be open for business by the third quarter of 2020 and have the projected capacity to conduct over 3,000 IVF treatment cycles per year. During the period between the acquisition of the relevant licenses and the opening of the new clinic, the Company will serve patients at the existing clinic owned by Rhea through cooperation arrangement. The new clinic is expected to offer a myriad of services, including IVF-ET (in vitro fertilization and embryo transfer), ICSI (intracytoplasmic sperm injection), PGS (preimplantation genetic screening)/PGD (preimplantation genetic diagnosis), third party IVF, various IVF technology and treatment options, and egg and sperm cryopreservation. Located near the border of the Boten Special Economic Zone, the clinic is in close proximity to China and will be accessible from Kunming, Yunnan province in approximately four hours via the high-speed railway due to be completed in 2021 as part of the Belt and Road Initiative. The directors of the Company believe that the business expansion in Laos will allow the Company to further expand its global reach by tapping into the Southeast Asian market and providing Chinese patients with an overseas option offering a wider range of service options and a lower price point, which is in line with the Company's internationalization strategy to expand out of China as well as catering for the surging patient flow from the Chinese market.

1

The Company has committed and will continue to implement its business strategies by expanding its network to address the unmet demand from Chinese patients, and to create long term value for its shareholders. The transaction contemplated in this announcement does not constitute a notifiable transaction of the Company under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and further announcement(s) will be made by the Company if and when required.

By order of the Board

Jinxin Fertility Group Limited

Wang Bin

Chairman

Hong Kong, March 3, 2020

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Zhong Ying, Ms. Yan Xiaoqing and Dr. John G. Wilcox, as executive Directors; Mr. Wang Bin, Mr. Fang Min, Ms. Hu Zhe and Mr. Dong Yang, as non-executive Directors; and Dr. Chong Yat Keung, Mr. Lim Haw Kuang, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive Directors.

• For identification purpose only

2